(Q46616119)

English

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

scientific article published in May 2008

Statements

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases (English)
Imatinib Target Exploration Consortium Study B2225

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit